XML 61 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill and Intangible Assets, Net (Tables)
 12 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amount of goodwill were as follows:
(In millions)U.S. Pharmaceutical InternationalMedical-Surgical SolutionsPrescription Technology SolutionsTotal
Balance, March 31, 2019$3,935 $1,446 $2,451 $1,526 $9,358 
Goodwill acquired— 62 — 14 76 
Acquisition accounting, transfers and other adjustments1 4 7 — 12 
Other changes/disposals(1)— (5)— (6)
Impairment charges— (2)— — (2)
Foreign currency translation adjustments, net(11)(67)— — (78)
Balance, March 31, 20203,924 1,443 2,453 1,540 9,360 
Goodwill acquired— 5 — — 5 
Acquisition accounting, transfers and other adjustments— — — 2 2 
Other changes/disposals(1)— — — (1)
Impairment charges— (69)— — (69)
Foreign currency translation adjustments, net40 156 — — 196 
Balance, March 31, 2021$3,963 $1,535 $2,453 $1,542 $9,493 
The impairment testing performed in 2019 resulted in the following impairment charges:
(In millions, except rates)
Quarter EndedReporting Unit
Segment (1)
Discount RateTerminal Growth Rate
Goodwill Impairment (2)
June 2018Pharmaceutical DistributionInternational8.0 %1.25 %$238 
(3)
June 2018Retail PharmacyInternational8.5 %1.25 %251 
(4)
June 2018Pharmaceutical DistributionInternational8.0 %1.25 %81 
(4)
March 2019Retail PharmacyInternational10.0 %1.25 %465 
(5)
March 2019Pharmaceutical DistributionInternational9.0 %1.25 %741 
(5)
Total$1,776 
(1)As described above, the Company implemented its new segment reporting structure in the second quarter of 2021 and its European Pharmaceutical Solutions segment and its Rexall Health business in Canada became part of the International segment. Amounts included herein were previously included within the former European Pharmaceutical Solutions segment.
(2)Represents pre-tax and after-tax amounts, except for an aggregate $20 million of tax charges related to the March 2019 Retail Pharmacy impairment. Total goodwill impairment for 2019 also included $21 million related to the Company’s Rexall Health business, within the International segment, recorded in the third quarter of 2019.
(3)Prior to implementing its new segment reporting structure in the first quarter of 2019, the Company’s European operations were considered a single reporting unit. Following the change in reportable segments, its European Pharmaceutical Solutions segment was divided into two distinct reporting units, Retail Pharmacy (“RP”), formerly Consumer Solutions, and Pharmaceutical Distribution (“PD”), formerly Pharmacy Solutions, for the purposes of goodwill impairment testing. This change required performance of a goodwill impairment test for these two new reporting units which resulted in a goodwill impairment charge as PD’s estimated fair value was lower than its reassigned carrying value.
(4)Both RP and PD projected a decline in the estimated future cash flows primarily triggered by U.K. government actions which were announced on June 29, 2018. An interim goodwill impairment test for these reporting units identified that their carrying values exceeded their estimated fair value and resulted in an impairment charge.
(5)As a result of the annual goodwill impairment test, the carrying values of the PD and RP reporting units exceeded their estimated fair value which required the Company to record impairment charges for the reporting units. These additional impairments were primarily due to declines in the reporting units’ estimated future cash flows and the selection of higher discount rates. The declines in estimated future cash flows were primarily attributed to additional government reimbursement reductions and competitive pressures within the U.K. The risk of successfully achieving certain business initiatives was the primary factor in the use of a higher discount rate. As of March 31, 2019 the entire remaining goodwill balances of both reporting units were impaired.
Schedule of information regarding intangible assets
Information regarding intangible assets is as follows:
March 31, 2021March 31, 2020
(Dollars in millions)Weighted-
Average
Remaining
Amortization
Period
(Years)		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount		Gross
Carrying
Amount		Accumulated
Amortization		Net
Carrying
Amount
Customer relationships12$3,739 $(2,269)$1,470 $3,650 $(1,950)$1,700 
Service agreements101,081 (513)568 994 (480)514 
Pharmacy licenses23497 (244)253 492 (232)260 
Trademarks and trade names12925 (394)531 808 (242)566 
Technology4150 (122)28 175 (111)64 
Other6254 (226)28 273 (221)52 
Total
$6,646 $(3,768)$2,878 $6,392 $(3,236)$3,156